IRIS UniCatt

Sora', Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.899
EU - Europa 3.795
AS - Asia 2.116
SA - Sud America 418
AF - Africa 53
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.292
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.838
DE - Germania 1.171
SG - Singapore 770
CN - Cina 728
SE - Svezia 707
IT - Italia 618
BR - Brasile 388
IE - Irlanda 247
FR - Francia 236
GB - Regno Unito 193
UA - Ucraina 193
IN - India 169
ID - Indonesia 167
FI - Finlandia 126
RU - Federazione Russa 103
KR - Corea 69
TR - Turchia 54
NL - Olanda 36
CA - Canada 35
HK - Hong Kong 35
BE - Belgio 28
CI - Costa d'Avorio 28
AT - Austria 27
CZ - Repubblica Ceca 21
IR - Iran 18
JP - Giappone 14
MX - Messico 14
ES - Italia 13
VN - Vietnam 13
PL - Polonia 12
BD - Bangladesh 9
HU - Ungheria 9
UZ - Uzbekistan 9
AR - Argentina 8
CH - Svizzera 8
EG - Egitto 7
LT - Lituania 7
PK - Pakistan 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
IQ - Iraq 6
AU - Australia 5
AZ - Azerbaigian 5
CL - Cile 5
EE - Estonia 5
IL - Israele 5
PE - Perù 5
BZ - Belize 4
MA - Marocco 4
PA - Panama 4
SA - Arabia Saudita 4
TW - Taiwan 4
ZA - Sudafrica 4
AL - Albania 3
DZ - Algeria 3
KE - Kenya 3
KG - Kirghizistan 3
LI - Liechtenstein 3
MD - Moldavia 3
NO - Norvegia 3
PT - Portogallo 3
PY - Paraguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
EC - Ecuador 2
ET - Etiopia 2
GE - Georgia 2
GR - Grecia 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
BH - Bahrain 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EU - Europa 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MC - Monaco 1
MK - Macedonia 1
MN - Mongolia 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
SV - El Salvador 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.292
Salva come PNG Salva come JPEG
Città #
Chandler 639
Singapore 452
Ashburn 412
Dublin 244
Woodbridge 178
Jakarta 158
Jacksonville 156
San Mateo 137
Dearborn 125
Nanjing 112
Wilmington 112
Beijing 93
Houston 91
Rome 91
Fairfield 90
Los Angeles 89
Milan 89
Hyderabad 85
Ann Arbor 84
Hefei 79
Cattolica 70
Moscow 70
Seattle 69
Seoul 67
Boston 66
Florence 62
Munich 61
New York 57
Princeton 57
Redmond 57
Frankfurt am Main 53
Nürnberg 53
Lancaster 51
Nanchang 51
Redwood City 50
Chicago 46
Helsinki 46
Marseille 46
Lawrence 41
Bremen 39
The Dalles 39
Izmir 35
Hong Kong 30
Abidjan 28
Brussels 28
Kunming 25
Lappeenranta 25
Norwalk 23
Santa Clara 23
Boardman 21
São Paulo 21
London 20
Nuremberg 19
Düsseldorf 18
Leawood 17
Pune 17
Toronto 17
Cambridge 16
Guangzhou 16
Hangzhou 16
Mountain View 16
Shanghai 16
Auburn Hills 15
Brno 15
Shenyang 15
Vienna 15
Tianjin 14
Fremont 13
Hebei 13
Jiaxing 13
Belo Horizonte 12
Lauterbourg 12
San Francisco 12
University Park 12
Portsmouth 11
Rio de Janeiro 11
Zhengzhou 11
Amsterdam 10
Changsha 10
Philadelphia 10
Tokyo 10
Brooklyn 9
Stockholm 9
Washington 9
Bologna 8
Budapest 8
Falkenstein 8
Mumbai 8
Paris 8
Porto Alegre 8
Tashkent 8
Turku 8
Buffalo 7
Hanoi 7
Phoenixville 7
Tampa 7
Augusta 6
Bexley 6
Council Bluffs 6
Curitiba 6
Totale 5.491
Salva come PNG Salva come JPEG
Nome #
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 373
Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis 323
Dasatinib first-line: Multicentric Italian experience outside clinical trials 267
Dasatinib first-line: Multicentric Italian experience outside clinical trials 267
Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization 245
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome 163
Correlation between paraproteinaemia and viral reactivation after allo-SCT 154
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. 149
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation 139
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 139
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 139
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 129
Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab. 129
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients 126
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 118
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration 115
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 115
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine 112
AB0 type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients 112
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 110
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 106
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 104
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 103
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo) 103
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 100
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 97
Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization 95
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 93
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 93
Non-tunnelled central venous catheters in adult stem cell transplantation recipients: an effective option 91
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 86
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 84
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 83
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 81
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 79
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study 78
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 78
Unrelated cord blood transplantation and post-transplant cyclophosphamide 77
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 77
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 76
SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation 76
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 76
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 75
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 74
the concomitance of lymphoma and breast carcinoma in the bone 74
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 73
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 71
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 70
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 69
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study 68
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 67
Unrelated cord blood transplantation and post-transplant cyclophosphamide 67
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 66
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 64
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 63
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 63
allogenic hemopoietic stem cell transplant in patients with acute myeloid leukemia prepared with busulfan and fludarabine or thiotepa busulfan and fludarabine a retrospective study 63
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 62
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 62
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 61
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 59
Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients 59
VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response 59
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 58
Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis 57
Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry 56
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 55
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 55
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 55
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 55
Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study 54
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. 54
The concomitance of lymphoma and breast carcinoma in the bone 54
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 54
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 53
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline 53
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 53
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 53
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 52
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 52
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic 51
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 51
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 51
Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR) 51
Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors 51
Second haploidentical stem cell transplantation for primary graft failure 50
CAR-T treatment is safe and effective in adult patients with Down syndrome and B-cell acute lymphoblastic leukemia (B-ALL) 50
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: A comprehensive review 49
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 48
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience 48
correction idelalisib exposure before allogenic stem cell transplantation in patients with follicular lymphoma an EBMT survey 47
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 47
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients 46
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. 45
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 44
Treatment patterns in patients with chronic-phase chronic myeloid leukaemia in routine clinical practice: The simplicity Italian population 44
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia 44
New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation 43
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience 43
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 42
Totale 8.617
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.276
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.276
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202058 0 0 0 0 0 0 0 0 0 0 0 58
2020/2021952 362 128 38 44 55 47 45 13 72 17 113 18
2021/2022912 76 39 34 41 65 24 18 139 49 62 179 186
2022/20232.038 253 243 147 252 209 273 95 150 257 50 82 27
2023/20241.291 42 352 58 88 42 151 98 75 26 69 120 170
2024/20252.752 98 80 216 173 254 117 115 133 432 312 744 78
Totale 10.538